As such, our in vitro models and breast cancer tissue spatial proteomics analysis do not demonstrate any causal effect of reduction of DCX + stromal cells in breast cancer and needs to be validated by in vivo model experiments. This evidence concerns the gene DCX and breast carcinoma.